General Announcement::Outcome of the Board Meeting held on 7th April, 2022

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
07-Apr-2022 22:44:12
Status
New
Announcement Sub Title
Outcome of the Board Meeting held on 7th April, 2022
Announcement Reference
SG220407OTHRWIFD
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
07/04/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Pursuant to Regulation 30 of the SEBI LODR, Regulations 2015, we wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee, Board at its meeting held today, has approved the Re-appointment of Mr. Glenn Saldanha (DIN- 00050607) as Chairman & Managing Director of the Company for a further period of 5 years with effect from 16th May, 2022; and the Re-appointment of Mrs. Cherylann Pinto (DIN- 00111844) as an Executive Director Corporate Services of the Company for a further period of 5 years with effect from 16th May, 2022.

Attachments

SGX_OUTCOME_07042022.pdf
Total size =766K